Analytical (technologies & services)

Boehringer Ingelheim licenses CureVac mRNA vaccine for up to $600m

Boehringer Ingelheim licenses CureVac mRNA vaccine for up to $600m

By Zachary Brennan

Boehringer Ingelheim will pay mRNA drug developer CureVac up to €465m ($600m) for an exclusive global license and development collaboration on CureVac’s potential mRNA vaccine in early clinical development for the treatment of lung cancer. 

Pfizer eyes Parkinson’s disease treatments with MedGenesis pact

Pfizer eyes Parkinson’s disease treatments with MedGenesis pact

By Zachary Brennan

Biotech company MedGenesis Therapeutix has granted Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments...

Arecor and CPI team on biologics stability research project

Arecor and CPI team on biologics stability research project

By Gareth Macdonald

Formulations that stop biopharmaceuticals being degraded by vials and syringes could help biopharmas avoid recalls and improve product shelf life says the UK team behind an industry focused research collaboration.

Demand for pre-prepared media drives Cherwell expansion

Demand for pre-prepared media drives Cherwell expansion

By Dan Stanton

Increased regulatory expectation in the environmental monitoring of microbiological media has driven demand for prepared solutions, says Cherwell Laboratories as it completes a facility expansion.

Waters sees chromatography growth despite flat Q1

Waters sees chromatography growth despite flat Q1

By Dan Stanton

Bioprocessing instrument manufacturer Waters has reported a flat Q1, but management predicts new products and a delayed release of capital from large pharma will lead to growth in 2014.

Majority of EU member states say ‘no’ to INNs for biosimilars

Majority of EU member states say ‘no’ to INNs for biosimilars

By Zachary Brennan

Most EU member states “strongly supported” the idea that biosimilars should be closely aligned with their reference products, according to a summary of the European Commission’s pharmaceutical committee meeting released Monday.

Follow us

Product Innovations